柳军副研究员个人简介

 

  

    柳军,女,现任中国药科大学新药筛选中心副研究员。2011年获中国药科大学药理学专业博士学位;2003年获美国加州州立大学生物化学硕士学位;1998-2001年在美国佛罗里达大学医学院任研究助理,从事分子生物学研究;1995-1996年在中科院上海药物所药理室任研究助理;1994年7月获中国药科大学中药药理专业学士学位。

    主要研究方向为代谢性疾病(糖尿病和肥胖)药物的机制研究、相关靶点寻找与确证、药物筛选模型和筛选新技术的建立以及新药开发。具体研究内容包括胰岛素和胰高血糖素等细胞信号传导通路的调控机制及其分子调控网络;基于胰岛b-细胞的保护和再生作用的天然产物的发现及系统性评价;针对高血脂及其诱发的动脉粥样硬化,开展胆固醇代谢调控的信号转导途径及相关药物机制研究;采用化学生物学技术,对新型光亲和标记的小分子探针靶标蛋白的研究,寻找化合物作用的新靶点。
    作为主要成员先后参与国家“十五”重大专项“新药筛选平台技术研究;国家“十五”重大专项“新型高通量筛选模型、化合物库建设和药物筛选”;国家“十一五”科技重大专项“新药筛选核心技术规范化平台建设及其科学应用”的研究;还承担和参与多项国家自然科学基金和地方科研项目。已发表论文60余篇,其中SCI论文44篇,参编英文专著1部;已申请专利9项,其中获得授权1项。
 
联系方式
Tel:025-83271043;Email:junliu@cpu.edu.cn
通信地址:南京市童家巷24号,中国药科大学新药筛选中心,邮编210009
 
代表性论文
1.Liying Zhang, Jizhe Dong, Jun Liu,* Luyong Zhang, Lingyi Kong, Hequan Yao and Hongbin Sun.* Synthesis and Biological Evaluation of Novel Pentacyclic Triterpene Derivatives as Potential PPARγ Agonists. Medicinal Chemistry 2013, 9, 118-125.
2.Jia Hao,Jun Liu, Xiaoan Wen, Hongbin Sun.* Synthesis and cytotoxicity evaluation of oleanolic acid derivatives.Bioorganic & Medicinal Chemistry Letters 2013, 23, 2074-2077.
3.Liying Zhang, Yingxia Zhang, Jizhe Dong, Jun Liu*, Luyong Zhang, Hongbin Sun*. Design and synthesis of novel photoaffinity probes for study of the target proteins of oleanolic acid. Bioorganic & Medicinal Chemistry Letters 2012, 22, 1036-1039.
4.Lei Zhang, Xiaojie Chen, Jun Liu, Qingzhang Zhu, Ying Leng, Xiaomin Luo, Hualiang Jiang, Hong Liu*. Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase. European journal of medicinal chemistry 2012, 58, 624-639. (co-first author)
5.Xuemei Chen, Jun Liu,Tao Wang, Jing Shang. Colchicine -induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicology in Vitro2012, 26, 649-655.
6.Jun Liu, Hongbin Sun, Jing Shang, Yuanyuan Yong, Luyong Zhang. Effect of Olive Pomace Extracts on Hyperlipidemia. Natural Product Research 2011, 25, 1190-1194.
7.Jun Liu, Ting He, Qian Lu, Jing Shang, HB Sun, Luyong Zhang. Asiatic acid preserves beta mass and mitigates hyperglycemia in streptozocin-induced diabetic rats. Diabetes Metabolism Research and Reviews 2010, 26, 448-454.
8.Jun Liu,Rajkumar Rajendram and Luyong Zhang. Effects of Oleanolic Acid and Maslinic Acid on Glucose and Lipid Metabolism: Implications for the Beneficial Effects of Olive Oil on Health. Book chapter in “Olives and Olive Oil in Health and Disease Prevention”, edited by Victor R. Preedy and Ronald Ross Watson. Elsevier, 2010, 1423-1429.
9.Li Liu, Zhenzhou Jiang, Jing Liu, Xin Huang, Tao Wang, Jun Liu, et al. Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Toxicology 2010, 271, 57-63.
10.Shikui Zhao, Weicheng Zhou, Jun Liu.Synthesis and HMG-CoA reductase inhibition of 2-cyclopropyl-4-thiophenyl-quinoline mevalonolactones. Bioorganic & Medicinal Chemistry 2009, 17, 7915-7923.
11.Xiaoan Wen, Hongbin Sun, Jun Liu, et. al. Naturally Occurring Pentacyclic Triterpenes as Inhibitors of Glycogen Phosphorylase: Synthesis, Structure-Activity Relationships and X-ray Crystallographic Studies. Journal of Medicinal Chemistry 2008, 51, 3540-3554.
12.Jun Liu,Hongbin Sun, Xiaofen Wang, Dongyan Mu, Hong Liao, Luyong Zhang. Effects of Oleanolic Acid and Maslinic Acid on Hyperlipidemia. Drug Development Research 2007, 68, 261-266.
13.Jun Liu, Hongbin Sun, Weigang Duan, Luyong Zhang. Maslinic acid reduces blood glucose and body weight in KK-Ay mice. Biological & Pharmaceutical Bulletin 2007, 30, 2075-2078.
14. Xiaoan Wen, Pu Zhang, Jun Liu, Luyong Zhang,Xiaoming Wu, Peizhou Ni, Hongbin Sun, Pentacyclic Triterpenes. Part 2: Synthesis and biological activity of maslinic acid derivatives as inhibitors of glycogen phosphorylase, Bioorganic & Medicinal Chemistry Letters 2006, 16, 722-726.(“Bioorganic and Medicinal Chemistry Letters” Most Cited Paper 2006-2009 Award)
15.Gary A. Visner, Fuhua Lu, Hailan Zhou, Jun Liu, Kristy Kazemfar, and Anupam Agarwal. Rapamycin Induces Heme Oxygenase-1 in Human Pulmonary Vascular Cells: Implications in the Antiproliferative Response to Rapamycin. Circulation 2003, 107, 911–916.